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a  b  s  t  r  a  c  t
Aim: To evaluate the tumor repositioning during gated volumetric modulated arc therapy
(VMAT) for liver stereotactic body radiotherapy(SBRT) treatment using implanted fiducial
markers and intrafraction kilovoltage (kV) images acquired during dose delivery.
Materials and methods: Since 2012, 47 liver cancer patients with implanted fiducial markers
were treated using the gated VMAT technique with a Varian Truebeam STx linear accelerator.
The  fiducial markers were implanted inside or close to the tumor target before treatment
simulation. They were defined at the maximum inhalation and exhalation phases on a 4-
dimensionnal computed tomography (4DCT) acquisition. During the treatment, kV images
were acquired just before the beam-on at each breathing cycle at maximum exhalation
and  inhalation phases to verify the fiducial markers positions. For the five first fractions of
treatment in the first ten consecutive patients, a total of 2705 intrafraction kV images were
retrospectively analyzed to assess the differences between expected and actual positions of
the  fiducial markers along the cranio-caudal (CC) direction during the exhalation phase.
Results: The mean absolute intrafractional fiducial marker deviation along the CC direction
was  1.0 mm at the maximum exhalation phase. In 99%, 95% and 90% cases, the fiducial
marker deviations were ≤4.5 mm, 2.8 mm and 2.2 mm, respectively.
Conclusion: Intrafraction kV images allowed us to ensure the consistency of tumor repo-sitioning during treatment. In 99% cases, the fiducial marker deviations were ≤4.5 mm
corresponding to our 5 mm treatment margin. This margin seems to be well-adapted to
the  gated VMAT SBRT treatment in liver disease.
© 2016 Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.∗ Corresponding author.
E-mail address: ludovic.bedos@icm.unicancer.fr (L. Bedos).
http://dx.doi.org/10.1016/j.rpor.2016.07.007
1507-1367/© 2016 Published by Elsevier Sp. z o.o. on behalf of Greater Poland Cancer Centre.






















































Table 1 – Patients characteristics.
Patient
index
Sex Age (y) PTV dose (Gy) VPTV (cm3)
1 F 85 5 × 10 106.3
2 F 59 5 × 10 66.7
3 M 62 5 × 10 55.7
4 F 82 8 × 5 224.3
5 M 70 10 × 5 141.2
6 M 56 10 × 5 367.2
7 M 63 10 × 5 83.5reports of practical oncology and 
.  Background
tereotactic Body Radiation Therapy (SBRT) is an effective
reatment procedure allowing the delivery of high radiation
oses in a few fractions leading to a high biological effec-
ive dose.1 The delivered doses are strictly conformed to the
arget with a rapid fall-off away from the tumor, protecting
he surrounding tissue, and the administration of high doses
hus requires a very accurate dose delivery to the tumor. For
bdominal tumors, the intrafraction motion provides some
mprecision in the dose delivery. In liver SBRT, the main chal-
enge is to take into account these motions. Liver motion is
omplex, consisting of translations, rotations and hysteresis.
t is mostly related to breathing and is usually the largest in
he cranio-caudal (CC) direction.2 Kitamura et al. analyzed
he liver tumor motion under tidal breathing and showed
 tumor motion up to 4 mm (range 1–12 mm),  9 mm (range
–19 mm)  and 5 mm (range 2–12 mm)  in the left–right (LR), CC
nd anterior–posterior (AP) directions, respectively.2,3
Several techniques can be used to manage tumor motion,
uch as active breath control, abdominal compression, respi-
atory gating and real-time tumor tracking.4–9 In this study,
e  used the respiratory gating technique with an external
urrogate placed on the patient’s abdominal wall associated
ith implanted fiducial markers to manage liver motion.5,10
he aim of this technique is to limit the radiation exposure
uring specific phases of the breathing cycle and to create
 correlation model between the internal target motion and
he external surrogate (skin surface), and finally to control
he radiation beam delivery thanks to the external surrogate
ignal.
Previous studies have shown that the position of the tumor
hanges both between the treatment fractions (interfraction)
nd within a single treatment fraction (intrafraction).11–15
Park et al. analyzed the interfraction and intrafrac-
ion liver motion variability constructing a 3-dimensional
otion trajectory of the fiducial markers implanted, at dif-
erent sites in the liver and as a function of the breathing
ycle. They reported, for 20 patients, a range of motion of
.0 ± 2.0 mm,  5.1 ± 3.1 mm and 17.9 ± 5.1 mm using the plan-
ing 4-dimensionnal computed tomography (4DCT), and of
.8 ± 1.6 mm,  5.3 ± 3.1 mm,  and 16.5 ± 5.7 mm using the cone-
eam computed tomography (CBCT), for the LR, AP and CC
irections, respectively. The authors found that the breathing-
nduced AP and CC motions were highly correlated. They
lso reported a significant variation during the interfrac-
ional gating window, with the largest having 29.4–56.4% range
etween fractions.12 Worm et al. described mean 3D intrafrac-
ion and intrafield motion ranges of internal markers during
iver SBRT of 17.6 mm (range 5.6–39.5 mm)  and 11.3 mm (range
.1–35.5 mm),  respectively, using standard X-ray imagers.13
In a recent study, Poulsen et al. used intrafraction kilovolt-
ge (kV) imaging during volumetric-modulated arc therapy
VMAT) liver SBRT to estimate the intra-treatment target
otion and to reconstruct the delivered target dose. They esti-
ated that the intrafraction motion caused a mean 3D target
osition error of 2.9 mm and a mean D95 reduction of 6.0%.14
Interfraction uncertainties have been well reduced thanks
o the daily use of image-guided setup techniques, such as8 F 64 5 × 10 18.9
9 F 81 5 × 10 93.4
10 M 65 5 × 10 39.1
kV imaging, fluoroscopy and kV CBCT. Intrafractional target
motion verification is the new challenge to achieve. Indeed,
it is crucial to make sure that the tumor always stays inside
the planning target volume (PTV) when the radiation beam is
turned on during the dose delivery. Because liver tumors can-
not be visualized by kV images, intrafractional target motion
verification relies on implanted fiducial markers. These can
be used during the patient’s setup and for the tumor motion
verification as they are implanted inside or close to the
target.16 Recent report evaluated the geometric accuracy of
the surrogate-based gated VMAT with a respiratory phantom
and also on real patients cases including liver tumors.17 Li
et al. showed in a phantom study a high geometric accuracy
(average error of 0.8 mm in the CC direction) when no target-
surrogate relation changes occurred during the treatment.
However, including a phase shift of 5% and 10% increased
the average errors to 2.3 and 4.7 mm,  respectively. The same
authors obtained similar trend with real human respira-
tory curves. For the patient study, they obtained an average
intrafraction positioning errors of 0.8, 0.9, and 1.4 mm in the
LR, AP and CC directions, respectively.17
In our study, data sets of kV images acquired during the
dose delivery using the Varian Novalis Truebeam Stx Linac and
the Intrafraction Motion Review software (IMR) (Varian Med-
ical Systems, Palo Alto, CA, USA) were used to evaluate the
reproducibility of tumor repositioning during multiple breath-
ing cycles during the liver SBRT treatment. The purpose of
this evaluation was to determine if the internal target volume
(ITV)/PTV safety margin used in our institution was appropri-
ate and if it could be reduced.
2.  Materials  and  methods
2.1.  Patients,  treatment  simulation  and  planning
Since 2012, 47 liver cancer patients with implanted fiducial
markers were treated using the gated VMAT SBRT technique
delivered using a Novalis Truebeam STx Linac. The present
study was based on intrafraction kV images data from the first
10 patients treated with this technique (Table 1).
The fiducial markers were implanted inside or close to the
tumor target before the treatment simulation. Most of the
patients had two to three fiducial markers implanted (Visicoil,
IBA) and some of them presented with multiple surgical clips
or prostheses due to a previous surgery. The implantation pro-
cedure was made 1–2 weeks before the planning scan allowing
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ion oFig. 1 – Marker points representing the maximum posit
the fiducial positions to be stabilized. The fiducial markers
were used for consistency verification of the liver motion and
not necessarily for patient set-up. No minimum number of
markers positioned in a specific geometry was required to
allow treatment of the patients.
For the treatment simulation and delivery, the patients
were placed in the supine position on a personalized body
shape cushion (Moldcare, Circo) with the arms above the head.
The patients breathed freely with no coaching before treat-
ment simulation. For each patient, an injected 3DCT and a
4DCT scan were acquired using an Optima CT580 16-slice CT
scanner (GE Medical Systems). The Real-time Position Man-
agement (RPM) system was used to record the respiratory
signal and synchronize it to the scan acquisition. The 4DCT
was acquired in the axial cine mode with a slice thickness
of 2.5 mm.  The 4DCT data were sorted into 10 phases of CT
images with 0% and 50% representing the maximum inhala-
tion and exhalation of the breathing cycle, respectively. An
average intensity projection (Ave-IP), maximum intensity pro-
jection (MIP) and minimum intensity projection (Min-IP) scans
were also generated.
Before the treatment planning, two to three more  4DCT
scans were acquired over 10 days for each patient in order to
study the reproducibility of the liver motion and of the fiducial
markers motions between each other.
The gross tumor volume (GTV) was delineated on the
injected 3DCT scan by a radiation oncologist. The ITV was
defined on the Ave-IP CT scan using the study of the fiducial
markers motions thanks to the dynamic CT scans (10 phases
CT images), and the MRI  acquisitions in deep inspiration and
deep expiration breath hold, and 4DCT-PET. The ITV was deter-
mined to encompass the full range of respiratory motion. The
PTV was created by adding a 5 mm isotropic margin from the
ITV to account for setup inaccuracies and intrafraction tumor
shifts. Organs at risks were delineated on the Ave-IP CT scan.
The fiducial markers were delineated on the maximum
inhalation (0%) and exhalation (50%) phase CT scans rep-
resenting their extreme positions, and on the MIP scan
representing their integral motion. The Ave-IP CT scan was
used as the planning CT.Six Mega-Voltage (MV) VMAT  (RapidArc) plans using the
Eclipse treatment planning system (Varian Medical Systems,
Palo Alto, CA, USA) were created, consisting of two half-arcf the fiducial markers in the inhale and exhale phases.
fields used to avoid contralateral organs with a maximum
dose rate of 600 monitor units/min. The dose calculations were
carried out on the Ave-IP CT scan using the Anisotropic Ana-
lytical algorithm. The choice of the fractionation scheme was
risk-adapted, dictated by the proximity to critical structures
and mainly to the radiation-induced liver disease risk. The
fractionation scheme was as follows: 5 × 10 Gy and 10 × 5 Gy
delivered in two weeks. Plans were normalized such that a
minimum of 95% of the PTV received 95% of the prescription
dose, and such that the maximum dose (D2%) in the PTV was
limited to 107% of the prescribed dose, i.e. a uniform PTV dose
distribution.
For each fiducial marker, two marker points were placed
to represent their extreme positions encompassing the global
motion of the target defining the ITV (Fig. 1).
2.2.  Patient  setup  and  verification
Daily, for each patient, the RPM block was fixed to the patient’s
abdomen surface at the same place than the treatment sim-
ulation. The breathing signal generated by this block was
recorded. An upper and lower gating threshold was defined
surrounding this breathing signal, representing the daily
breathing cycle amplitude.
The patient was first set up acquiring a CBCT scan accord-
ing to a pelvis acquisition protocol (125 kV, 1056 mA  s). The
patient images were registered based on the liver informa-
tion and on the fiducial marker positions. Because of the CBCT
acquisition time (about 60 s), an average representation of the
organs and tumor motions were included in those images.
Consequently, the ITV of the day represented on the CBCT
acquisition was compared to the planning ITV on the Ave-IP
reference CT scan. This process leads to a correlation model
between internal and external information. If the information
were in good agreement, the daily breathing cycle ampli-
tude was validated. The internal tumor and fiducial markers
motions represented by the external RPM block were similar
to those defined during the treatment planning.
During the second setup step, two orthogonal kV images
were acquired, first at the maximum exhalation phase and
then at the maximum inhalation phase (Fig. 2). The aim of
those acquisitions was to verify the extreme positions of the
ITV by checking the positions of the fiducial markers and
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Fig. 2 – Two orthogonal kV images acquired at the maximum exhalation phase (a) and at the maximum inhalation phase
(b). Upper and lower green cross represent the expected position in exhale phase and inhale phase, respectively. (For






























total number of intrafraction kV images acquired during treat-
ment ranged from 8 to 99, mainly depending on the breathingompare them with the expected positions according to the
lanning step.
The orthogonal kV images at the maximum exhalation
hase were acquired first because it is the most reproducible
hase and because it allows the adjustment of a baseline shift
f necessary. If it was the case, and because of the spatial res-
lution accuracy is better than for the CBCT scan, refining the
atient setup was allowed.
The orthogonal kV images at the maximum inhalation
hase were then acquired, and the marker positions were
ompared again. At this stage, refining the patient setup
as not authorized because of the eventuality of inhalation-
mplitude changes. If the marker positions did not correspond
o their expected positions, an adjustment of the gating
hreshold was performed, i.e. the total breathing amplitude
as not used for the treatment (Figs. 3 and 4).
.3.  Treatment  delivery  and  intrafraction  kV  images
he MV  beam was triggered by the RPM system. The
mplitude-based gating was used for all the treatments. Dur-
ng the gated VMAT delivery, the beam was turned on/off
utomatically when the breathing signal crossed the gating
hreshold, and a kV image  (75 kV, 4 mA s, 0.3 mGy/image)18
as acquired when the signal entered the gate just before
V beam on. That information allowed to continuously verify
he consistency of the daily breathing cycle model controlling
hat the external–internal correlation still remained in good
oncordance.
The fiducial markers positions were compared to their
xpected positions in real time applying a 5 mm tolerance limit
orresponding to the ITV/PTV margin. If the fiducial mark-
rs were shifted, the beam was turned off manually and kV
mages were still acquired until the markers came back to anacceptable position. Otherwise the MV beam was stopped and
the patient was aligned again.
2.4.  Motion  analysis
The intrafraction kV images were used retrospectively to ver-
ify and evaluate the reproducibility of the tumor repositioning
during gated VMAT treatment because they were acquired
just before MV beam-on at each period of the breathing cycle.
This analysis of the tumor motion was achieved by studying
the marker position motions as they were implanted inside
or close to the tumor target. The marker positions estimated
from the kV images were compared to their reference pos-
itions defined on the orthogonal kV images during the second
step of the patient setup. This analysis was made on the kV
images acquired at the maximum exhalation phase. The dis-
tance shift between the expected and actual fiducial marker
positions along the CC direction was estimated for 10 liver
patients using the Offline Review application (Varian Medical
System).
3.  Results
For the 10 patients with liver cancer included in the study,
a total of 2705 intrafraction kV images were analyzed for
the first 5 fractions of the treatment. For one fraction, thesignal changes (Table 2). Table 2 and Fig. 5 present the esti-
mated intrafractional fiducial marker displacement along the
CC direction at the maximum exhalation phase compared to
their reference positions for all patients.
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 perfFig. 3 – Adjustment of the gating threshold
The mean (xmean ± SD mm)  intrafractional fiducial marker
displacement along the CC direction was −0.1 ± 1.4 mm with
a 95% confidence interval of [−2.9, 2.6 mm].  The mean abso-
lute intrafractional fiducial marker deviation at the maximum
exhalation phase was 1 mm (Table 3 and Fig. 6a and b).In 99%, 95% and 90% cases, the deviations of the fidu-
cial markers were ≤4.5 mm,  2.8 mm and 2.2 mm,  respectively
(Fig. 6b).
Fig. 4 – kV images acquired at each breathing cycle before MV  be
phase (b).ormed at the maximum inhalation phase.
4.  Discussion
We have presented our gated VMAT liver SBRT protocol
using implanted fiducial markers and intrafraction kV images
acquired at the beginning of the beam delivery at every breath-
ing cycle during treatment (i.e. 2 kV images per breathing cycle
at maximum exhalation and inhalation phases). Our study
was  based on the amplitude-based respiratory gating with
am-on at the maximum exhalation (a) and inhalation
reports of practical oncology and radiotherapy 2 2 ( 2 0 1 7 ) 132–140 137





kV images for one
fraction
Total number of
kV images for the
five fractions
Intrafractional fiducial marker displacement along the
CC direction at the maximum exhalation phase (mm)









1 62 84 362 −4.3 1.7 6.0 −0.5 0.9
2 45 99 329 −5.6 5.7 11.3 −0.2 1.9
3 52 92 339 −3.9 5.2 9.1 −0.2 1.7
4 8 72 239 −3.2 7.5 10.7 0.3 1.9
5 26 57 205 −1.9 2.0 3.9 0.2 0.8
6 24 65 245 −3.2 2.0 5.2 −0.7 1.2
7 38 70 285 −3.0 3.0 6.0 −0.2 0.7
8 37 55 235 −3.3 6.3 9.6 0.4 1.3
9 29 86 310 −3.0 2.5 5.5 0.0 1.0







Fig. 5 – Frequency distributions of the fiducial marker dis
aily adjustment of the gating parameters. The present arti-
le aimed to describe the evaluation of the fiducial position
eproducibility at the maximum exhalation phase.In liver SBRT, the use of fiducial markers is major to
ontrol the respiration-induced motion during the treat-
ent. Many  studies on liver motion characterization usingment along the CC direction ordered by patient number.
markers have been published.12,16,19 Seppenwoolde et al.
showed that the tumor position can be accurately predicted
using implanted markers considering that there is a real influ-
ence of the marker-tumor distance on the set-up accuracy.
They also showed that the diaphragm dome was the second
best predictor of tumor motion and that it could be used as a
138  reports of practical oncology and radiotherapy 2 2 ( 2 0 1 7 ) 132–140




Intrafractional fiducial marker displacement along the CC direction at the maximum exhalation phase
(mm)
Min  (caudal) Max Mean Mean absolute
dev
SD () Confidence interval (95%)
(cranio) (xmean)
2705 −5.6 7.5 −0.1 
surrogate for tumor located close to it.19 Park et al. studied the
liver motion characteristics based on fiducial markers tracked
with the X-rays projections of the CBCT scans. Their results
showed large variations in liver motion and their conclusion
was similar to those of Seppenwoolde et al., mainly that the
distance between the markers and the tumor was a major
element to track.12 Intrafraction kV images can be used to con-
trol and verify the fiducial marker positions during treatment
delivery.17 These images allowed us to ensure the consistency
of tumor repositioning during the treatment by frequently
controlling the external–internal correlation model. Beddar
et al. investigated the correlation between the motions of an
external marker and of internal fiducials markers implanted
in the liver for 8 patients undergoing 4DCT. They specified
that there often was a good correlation between the inter-
nal fiducial marker motion imaged by 4DCT and the external
marker motion, and that they were best correlated during
expiration.10 Our results thus confirm those of Beddar et al.
Fig. 6 – (a) Frequency and (b) cumulative frequency of all
intrafraction displacement along the CC direction for the 10
patient’s data combined.iation [xmean − 2, xmean + 2]
1.0 1.4 [−2.9, 2.6]
according to whom actual and expected positions of the fidu-
cial markers at the maximum exhalation phase are generally
well concordant (Fig. 5). These frequency distributions showed
that there is an accurate patient’s alignment reproducibility
at the maximum exhalation phase. Indeed, in our protocol, if
the fiducial markers shifted during the treatment because of
the patient’s movements or intrafractional organ motions, the
patient was re-aligned. This explains why our frequency distri-
butions were centered to the expected position of the fiducial
markers in CC. However, we  also observed some deviations.
Results showed that in 99% cases, the fiducial marker devia-
tions at the maximum exhalation phase were ≤4.5 mm with a
95% confidence interval of [−2.9, 2.6 mm].20 These results are
in accordance with our ITV/PTV margin protocol, indicating
that it seemed to be well adapted to the gated VMAT  SBRT
treatment in liver disease. Moreover, they are close to the rec-
ommendation reported by Ge et al. to use at least a 2.5 mm
safety margin to account for gating and setup uncertainties.8
Li et al. reported results from 5 patients (2 pancreas, 2 liv-
ers and 1 lung) using intrafraction kV images verification of
gated VMAT. They obtained average intrafraction positioning
errors for the 5 patients of 0.8, 0.9 and 1.4 mm in the LR, AP
and CC directions, respectively. The errors in the CC direction
appeared to be a dominant factor for lung and liver patients.17
In a recent study, Winter et al. quantified random uncer-
tainties in robotic radiosurgical treatment of liver lesions
with real-time respiratory motion management by analyz-
ing logged tracking information and isolated X-rays images
collected before beam delivery. They estimated the overall
random uncertainty by quadratically summing correlation
determined by periodic X-ray imaging, prediction, and end-
to-end targeting errors. They particularly showed that the
95th percentile absolute correlation errors were of 3.3 mm  in
the cranio-caudal direction, whereas the 95th percentile abso-
lute radial prediction errors were of 0.5 mm.  The overall 95th
percentile random uncertainty was of 4 mm in the radial direc-
tion. They demonstrated that model correlation errors are
the primary random source of uncertainty in Cyberknife liver
treatment and they suggested that the target should be within
4 mm of the target volume for 95% of the beam delivery.21
These results coming from another SBRT technique are close
to those we obtained with our ITV/PTV margin protocol. In
our study, 95% of the deviations of the fiducial markers were
≤2.8 mm.
Our liver treatment protocol was recently improved by
including the use of the Automatic Beam-Hold software (ABH,
Varian Medical Systems). The ABH algorithm allows the auto-
matic detection of the fiducial markers on the intrafraction kV
images, turning on or holding off the MV  beam automatically
if the markers were in a good or displaced position, respec-
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ventuality to treat patients only during the end of the expira-
ory phases thus minimizing ITV and decreasing the ITV/PTV
afety margin to better protect the surrounding healthy tissue.
A shortcoming of this method is that the MV beam is turned
ff during the majority of the respiratory cycle (i.e. loss of duty
ycle), resulting in an increase of the treatment time. Never-
heless, a faster delivery of the dose is allowed by the recent
evelopment of the Flattening Filter Free beams with a dose
ate up to 1400 monitor units/min for 6 MV beams.22,23 Vas-
iliev et al. assessed the feasibility of stereotactic radiotherapy
or early stage lung cancer using photon beams without a flat-
ening filter. They showed that the total beam-on time was
educed by factor of 2.31 (±0.02 SD) for plans using only 6 MV
eams with the filter removed, increasing the feasibility and
he efficiency of gated treatments.24 The next challenge is to
reat the patients with liver disease with a gated VMAT SBRT
echnique including an end-exhalation phase (40–50–60%) gat-
ng and Flattening Filter Free beams.
.  Conclusion
his study presented our gated VMAT  liver SBRT protocol
ased on the use of implanted fiducial markers and intrafrac-
ion kV images. Tumor repositioning was evaluated thanks
o the analysis of intrafraction kV images. We  show that in
9% cases, the fiducial marker deviations were ≤4.5 mm in
xhalation phase corresponding to our 5 mm ITV/PTV margin.
his margin seems to be well adapted to the gated VMAT  liver
BRT treatment. The use of intrafraction kV images is crucial
o verify the consistency of the correlation between an exter-
al surrogate and an internal target motion during the dose
elivery.
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